Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial

Journal of Clinical Oncology

Volumn 20, Issue 11, 2002, Pages 2651-2657

  Souglakos, J ^a   Mavroudis, D ^a   Kakolyris, S ^a   Kourousis, Ch ^a   Vardakis, N ^a   Androulakis, N ^a   Agelaki, S ^a   Kalbakis, K ^a   Tsetis, D ^a   Athanasiadis, N ^a   Samonis, G ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PATIENT COMPLIANCE; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0036605387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.015     Document Type: Article

References (31)

1. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
3. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
4. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
5. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
6. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
7. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivates presently in clinical trials
8. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
9. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
10. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial
11. Oxaliplatin (L-OHP): A new reality in colorectal cancer
12. Ongoing and unsaid on oxaliplatin: The hope
13. Oxaliplatin effects on naked and intracellular DNA
14. Computer modeling of the primary cisplatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition
15. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
16. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
17. Optimal combination between irinotecan (CPT-11), oxaliplatin (L-OHP) and fluorouracil-folinic acid (FUFOL): Experimental data on human colorectal cell lines
18. Mathematical model for relating sensitivity of tumors to their spontaneous mutation rate
19. A phase I/II study of CPT-11 plus L-OHP and 5-FU/LV in patient with metastatic colorectal cancer
20. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
21. Non-parametric estimation from incomplete observations
22. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line treatment of metastatic colorectal cancer (MCRC)
23. Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer
24. Irinotecan in the treatment of colorectal cancer: Clinical overview
25. Dose finding study of weekly 24h 5FU (FUci) in alternated association with CPT-11 and oxaliplatin (OXA) given for 4 or every 5 weeks in advanced colorectal cancer (ACRC) patients (Pt)
26. Final results of oxaliplatin (LOHP) + irinotecan (CPT-11) and FU-FOL (LV5FU2) combination and pharmacokinetic (PK) analysis in advanced colorectal cancer (ACRC) patients (Pt)
27. Irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hrs continuous infusion every two weeks in metastatic colorectal cancer patients (Pts)
28. Irinotecan, oxaliplatin plus 5-FU/leucovorin in advanced colorectal cancer
29. Interactions of oxaliplatin with the topoisomerase I inhibitors topotecan and SN-38